Biologics growth and resilient GLP-1 demand support long-term earnings after a 14% pullback; see margin outlook, 2026 profit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback